Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide (AVE0010) in Type 2 Diabetes Not Controlled with Metformin
NCT00763451Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2008
- Primary completion
- Jan 2011
- Modality
- Peptides
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of lixisenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sanofi. Primary endpoint: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 24 weeks. Started Sep 2008; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00763451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00763451.